Cargando…
Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
PURPOSE: The aim of this study was to quantitatively compare five commercial dosimetric software platforms based on the analysis of clinical datasets of patients who benefited from peptide receptor radionuclide therapy (PRRT) with (177)Lu‐DOTATATE (LUTATHERA(®)). METHODS: The dosimetric analysis was...
Autores principales: | Mora‐Ramirez, Erick, Santoro, Lore, Cassol, Emmanuelle, Ocampo‐Ramos, Juan C., Clayton, Naomi, Kayal, Gunjan, Chouaf, Soufiane, Trauchessec, Dorian, Pouget, Jean‐Pierre, Kotzki, Pierre‐Olivier, Deshayes, Emmanuel, Bardiès, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589428/ https://www.ncbi.nlm.nih.gov/pubmed/32632928 http://dx.doi.org/10.1002/mp.14375 |
Ejemplares similares
-
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [(177)Lu-[DOTA0, Tyr3]-octreotate
por: Santoro, Lore, et al.
Publicado: (2018) -
Clinical implementation of PLANET® Dose for dosimetric assessment after [(177)Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
por: Santoro, Lore, et al.
Publicado: (2021) -
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
por: Loke, Kelvin S. H., et al.
Publicado: (2011) -
Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021) -
Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)